EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmaceutical Market Failure, Subsequent Policy, and its Obstacles in China

Yaning (Walter) Liu

Scholarly Review Journal · 2021

DOI: 10.70121/001c.121650 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Scholarly Review Journal, 2021. Verfasst von Yaning (Walter) Liu. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is a perception today among many Chinese people that domestically produced drugs are inferior in quality to foreign ones, which is partly true considering that China is not researching and developing its own medicine at a high enough rate. The economic issue of the pharmaceutical market in China is that foreign drugs require high-cost and out-of-pocket payment because the medical insurance from the government only pays for domestic medicine, which doesn’t cover certain diseases due to issues such as a slow drug approval period and low R&D investment. In order to deal with this problem, in October of 2017, the Chinese government implemented a policy that allowed importing of foreign medication and medical tools that are urgently needed by Chinese people through an easier procedure. However, this policy is hard to implement since it disadvantages domestic pharmaceutical producers and regulatory authorities, generating voices of opposition. Considering the obstacles, this paper argues that the optimal policy is to reimburse the cost of more foreign drugs until the quality of Chinese drugs improves through R&D. The money for R&D will come from government tax breaks, especially for private companies, which constitute 70% of the industry. In order to make up for the money lost in tax breaks, the government should spend less in other sectors, considering the importance of healthcare to citizens. With a larger healthcare budget, more money can be invested in state-owned pharmaceutical companies in China, who are also responsible for producing domestic medicine.

Zitieren

APA

Liu, Y. W. (2021). Pharmaceutical Market Failure, Subsequent Policy, and its Obstacles in China. Scholarly Review Journal. https://doi.org/10.70121/001c.121650

Vancouver

Liu YW. Pharmaceutical Market Failure, Subsequent Policy, and its Obstacles in China. Scholarly Review Journal. 2021. doi:10.70121/001c.121650

BibTeX
@article{Liu2021,
  author = {Liu, Yaning (Walter)},
  title = {Pharmaceutical Market Failure, Subsequent Policy, and its Obstacles in China},
  journal = {Scholarly Review Journal},
  year = {2021},
  doi = {10.70121/001c.121650}
}
Kostenlos starten →